Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of pulmonary vein isolation PVI using high power short duration HPSD radiofrequency energy in patients with paroxysmal or persistent atrial fibrillation AF. This prospective, multi-center study aims to understand the relationship between clinical and procedural factors and the success and safety of this ablation method, with a follow-up period of 12 months to monitor AF recurrence. Patients with paroxysmal or persistent AF will undergo catheter ablation using approved mapping systems and catheters. The procedure involves sedation or anesthesia, vascular access through femoral or subclavian veins, and placement of diagnostic and ablation catheters in the left atrium. Ablation is performed with a QDot Micro catheter delivering radiofrequency energy in specific modes to isolate pulmonary veins. Effectiveness of the isolation is confirmed during the procedure, and any reconnections are addressed. Post-procedure, an ECG and optional echocardiogram are done to check for complications. During the 12-month follow-up, patients will have regular assessments at 3 months including history, physical exams, ECG, and 24-hour Holter monitoring to detect arrhythmia recurrence. Additional follow-ups between 6 and 12 months help confirm freedom from arrhythmia if no symptoms are reported. Researchers will measure outcomes such as arrhythmia recurrence rates, procedural times, vein reconnection, anesthesia impact, pain perception, and fluoroscopy duration to evaluate the procedures overall safety and efficacy.
Actively Recruiting
Researchers are studying patients experiencing arrhythmic storm, a serious heart condition characterized by frequent and sustained ventricular arrhythmias that do not respond to standard antiarrhythmic drugs. This international multicenter observational study aims to evaluate the safety and effectiveness of Percutaneous Stellate Ganglion Block PSGB in reducing arrhythmic relapses in such emergency cases. The study is coordinated by Fondazione IRCCS Policlinico San Matteo of Pavia, Italy, and addresses a gap in large-scale data on this procedure. Participants who meet the criteria will receive PSGB using either the anatomical or echo-guided approach. Depending on patient needs, the procedure may involve a single anesthetic injection or continuous anesthetic infusion via a catheter connected to a pump. The study compares the number of arrhythmic events and defibrillations before and after PSGB treatment and notes any complications occurring within 12 hours post-procedure. During participation, patients will be monitored closely for arrhythmic relapses using defibrillation counts and anti-tachycardia pacing data. Complications such as hematomas, vascular injuries, and nerve damage will be recorded. Data are collected using a secure electronic system, with effectiveness measured by arrhythmic event reduction in the 12 hours following PSGB compared to the 12 hours prior. The study plans to enroll patients over several years with ongoing safety and outcome evaluations.
Actively Recruiting
This research focuses on adult patients newly diagnosed with myelodysplastic syndrome MDS, aiming to collect epidemiological data across Italy. The study seeks to develop a network of regional registries that use a standardized electronic case report form to store and process anonymous patient data. This network also aims to integrate Italian data with international MDS registries for broader analysis. Participants contribute data to the registry without receiving specific treatments through this study. The data collected will include detailed patient information related to their MDS diagnosis and progression over time. The study spans several years, allowing long-term observation and aggregation of epidemiological data. Throughout the study, researchers will review important outcomes such as the incidence and prevalence of MDS, overall response rates, survival rates, progression to acute myeloid leukemia, and progression-free survival over a six-year period. Participants provide data over time, and the registry helps monitor these outcomes to better understand the disease and its impact.
Actively Recruiting
Researchers are conducting the PREgnancy and FERtility PREFER study to improve care and understanding of fertility preservation and pregnancy issues in young women with breast cancer. This comprehensive program includes two parts one focusing on fertility preservation choices and outcomes, and the other on managing breast cancer diagnosed during pregnancy and the health of children born after cancer treatment exposure. The study collects data over a long time to better understand these important topics. The PREFER study gathers information on fertility preservation strategies available in Italy, including patients preferences, the techniques used, and their success and safety. It also tracks breast cancer cases diagnosed during pregnancy or soon after, monitoring pregnancy management, child health after exposure to cancer treatments in the womb, and outcomes for survivors who become pregnant later. The program is carried out across multiple Italian centers under a research group. Participants provide data through medical records and follow-up over many years. Researchers measure how many patients choose fertility preservation, the types of treatments given during pregnancy, pregnancy complications, survival rates, ovarian function recovery, number of eggs preserved, and pregnancies achieved after treatment. They also evaluate hormone changes during chemotherapy and the health of children born to affected mothers. The study continues for up to 15 years to gather long-term safety and outcome information.
Actively Recruiting
This research investigates the use of a structured telenursing program for women with breast cancer receiving cyclin-dependent kinase CDK inhibitor therapy. These treatments can cause side effects that reduce treatment adherence and quality of life. The study aims to determine if scheduled remote nursing follow-ups can help detect and manage these side effects earlier to improve clinical outcomes and reduce complications such as hospital visits and treatment interruptions. Participants are randomly assigned to receive either standard nursing care or standard care plus a structured telenursing intervention. The telenursing program involves scheduled telephone or video consultations at set times during treatment cycles, where trained nurses assess symptoms, provide education, support medication adherence, and identify early signs of treatment toxicities. When significant issues arise, patients are referred promptly to physicians for further management. During the study, participants undergo regular assessments of side effects, treatment adherence, hospital visits, and quality of life using questionnaires and clinical data collected at baseline and throughout up to six months of treatment. The study measures the incidence and severity of adverse events, emergency visits, hospitalizations, and patient-reported outcomes to evaluate the effectiveness of the telenursing intervention compared to standard care.